The effect of spiramycin in prevention of toxoplasma infection in neonates

The effect of spiramycin in prevention of toxoplasma gondii infection from mothers with acute toxoplasmosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170201032346N5

Enrollment

Registered

2020-12-26

Start date

2007-09-23

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Toxoplasmosis. Congenital toxoplasmosis

Interventions

Intervention group: Mothers will be treated with 1gr of spiramycin every 8 hours until delivery and their offspring will be followed for a year..

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Positive Anti-Toxoplasma gondii IgG and IgM antibodies Signed informed consent

Exclusion criteria

Exclusion criteria: High positive avidity test Negative Anti-Toxoplasma gondii IgM antibodies Positive screening tests for fetal anomalies

Design outcomes

Primary

Measure	Time frame
Prevalence of congenital toxoplasmosis. Timepoint: Evaluation of infant until a year after birth. Method of measurement: Physical examination and performing diagnostic tests based on patient complaint.;Fetal abortion. Timepoint: from diagnosis and initiation of treatment until delivery. Method of measurement: History, physical examination and sonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFirouzi Hossein

Mazandaran University of Medical Sciences

firoozihosein@mazums.ac.ir+1 155230181

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026